Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Aplastic anemia and concomitant autoimmune diseases
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1193518
Author(s) Stalder, Magnus P; Rovó, Alicia; Halter, Jörg; Heim, Dominik; Silzle, Tobias; Passweg, Jakob; Rischewski, Johannes; Stern, Martin; Arber, Caroline; Buser, Andreas; Meyer-Monard, Sandrine; Tichelli, André; Gratwohl, Alois
Author(s) at UniBasel Tichelli, André
Rovó, Alicia
Rischewski, Johannes
Arber Barth, Caroline
Heim, Dominik A.
Meyer-Monard, Sandrine
Gratwohl, Alois A.
Passweg, Jakob R.
Year 2009
Title Aplastic anemia and concomitant autoimmune diseases
Journal Annals of hematology : organ of Deutsche Gesellschaft für Hämatologie und Onkologie, Gesellschaft für Thrombose- und Hämostaseforschung, Österreichische Gesellschaft für Hämatologie und Onkologie
Volume 88
Number 7
Pages / Article-Number 659-65
Keywords Aplastic anemia, Autoimmune diseases, Antithymocyte globulin
Abstract The association of aplastic anemia (AA) with other autoimmune diseases (AID) has been described but so far not systematically evaluated. We assessed the incidence and the outcome of concomitant AID in a retrospective, single-center study of 243 patients with severe AA treated between 1974 and 2006 with either immunosuppression (186) or hematopoietic stem cell transplantation (57) and a median follow-up time of 9.3 years (0-33). Clinically manifest AID were observed in 24 out of 243 (10 +/- 3.7%) patients. Age at diagnosis of AA was significantly younger in patients without AID compared to patients with AID (median, 20 versus 52 years; P < 0.001). In 12 patients where the diagnosis of AID was done before AA therapy, response to antithymocyte globulin was good for AA (ten out of 12) but not for AID (2 out of 12). In 13 patients in which AID occurred after first-line therapy, the median time to the AID was 7 years (range 3 months-27.5 years).
Publisher Springer
ISSN/ISBN 0939-5555
edoc-URL http://edoc.unibas.ch/dok/A6003761
Full Text on edoc No
Digital Object Identifier DOI 10.1007/s00277-008-0671-9
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/19139895
ISI-Number WOS:000266260300009
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.330 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/04/2024